Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 722

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 722
---
 clinical costs, $ 561 of prepaid insurance and $ 171 of other prepaid costs. As of December 31, 2023, prepaid expenses were $ 8,154 , consisting of $ 7,245 of prepaid R&D clinical costs, $ 492 of prepaid insurance, and $ 417 of other prepaid costs.

9. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ 
 ​ | ​ |                  ​ 
 September 30, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:------------------------------------|:--|:--|-------------------:|:--|:--|------------------:|
| Accounts payable                    | ​ | $ |              2,541 | ​ | $ |            11,583 |
| Accrued research projects           | ​ |   |              1,490 | ​ |   |             4,343 |
| Accrued compensation and benefits   | ​ |   |              1,173 | ​ |   |             6,519 |
| Accrued professional fees and other | ​ |   |              1,418 | ​ |   |             3,147 |
| Total                               | ​ | $ |              6,622 | ​ | $ |            25,592 |

10. Royalty Purchase and Sale Agreement During the fourth quarter of 2023, the Company, through its wholly-owned subsidiary Cara Royalty Sub, entered into the HCR Agreement with HCR, pursuant to which Cara Royalty Sub sold, or agreed to sell, to HCR certain of its rights to receive royalty payments, or the Royalties, due and payable to Cara Royalty Sub (as assignee of the Company) under the Maruishi Agreement and Vifor Agreement No. 2. (as defined below), collectively the Covered License Agreements, in exchange for up to $ 40,000 . The Company has retained all of its rights, title and interest in, to and under the Covered License Agreements that relate to any non-intravenous formulation of difelikefalin. Under the terms of the HCR Agreement, Cara Royalty Sub received an upfront payment of $ 16,915 in November 2023, representing the $ 17,500 to which the Company was initially entitled, net of advisory fees and certain of HCR’s transaction-related expenses which the Company agreed to reimburse.